These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 22095631

  • 21. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.
    Lane J, Langdahl B, Stone M, Kurth A, Oates M, Timoshanko J, Wang Z, Libanati C, Cosman F.
    Osteoporos Int; 2024 Jul; 35(7):1195-1204. PubMed ID: 38573517
    [Abstract] [Full Text] [Related]

  • 22. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
    Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A.
    J Bone Miner Res; 2019 Mar; 34(3):419-428. PubMed ID: 30508316
    [Abstract] [Full Text] [Related]

  • 23. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
    Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T.
    J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
    [Abstract] [Full Text] [Related]

  • 24. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
    Moen MD, Keam SJ.
    Drugs Aging; 2011 Jan 01; 28(1):63-82. PubMed ID: 21174488
    [Abstract] [Full Text] [Related]

  • 25. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.
    McClung MR, Zanchetta JR, Høiseth A, Kendler DL, Yuen CK, Brown JP, Stonkus S, Goemaere S, Recknor C, Woodson GC, Bolognese MA, Franek E, Brandi ML, Wang A, Libanati C.
    J Clin Densitom; 2013 Jan 01; 16(2):250-6. PubMed ID: 22572531
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.
    Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Mellström D, Radominski SC, Reginster JY, Resch H, Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S.
    J Clin Endocrinol Metab; 2013 Nov 01; 98(11):4483-92. PubMed ID: 23979955
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Denosumab for treatment of postmenopausal osteoporosis.
    Chitre M, Shechter D, Grauer A.
    Am J Health Syst Pharm; 2011 Aug 01; 68(15):1409-18. PubMed ID: 21785030
    [Abstract] [Full Text] [Related]

  • 32. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
    Nakamura T, Matsumoto T, Sugimoto T, Shiraki M.
    Osteoporos Int; 2012 Mar 01; 23(3):1131-40. PubMed ID: 21927920
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.
    Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD.
    Bone; 2003 Oct 01; 33(4):522-32. PubMed ID: 14555255
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials.
    Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, Khosla S, de Papp A, Mitlak B, Cauley JA, McCulloch CE, Eastell R, Bouxsein ML, Foundation for the National Institutes of Health Bone Quality Project.
    Lancet Diabetes Endocrinol; 2020 Aug 01; 8(8):672-682. PubMed ID: 32707115
    [Abstract] [Full Text] [Related]

  • 39. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S.
    Lancet Diabetes Endocrinol; 2017 Jul 01; 5(7):513-523. PubMed ID: 28546097
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.